MDMX is a novel therapeutic target in cervical carcinoma by inhibiting p53 function

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-064-Tuesday
• By: WANG, Hongbo (Yantai, China)
• Co-author(s): Jingwen Zhang: Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China
  Hongbo Wang: Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China;Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China
  Fenghua Fu: Key lab of Molecular Pharmacology and drug evaluation, Yantai University, Yantai, China
  
• Abstract:

  Backgrounds

  Cervical cancer is among the most common malignant tumours and the fourth leading cause of cancer death among women worldwide. MDMX, known as a mean to dampen p53 tumor-suppressor function, has recently been found to be overexpressed in certain types of human cancers. However, the role of MDMX in cervical carcinogenesis remains unclear.

  A

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login